Check out our publication on glycan therapeutics, an almost pharma-forgotten drug class! symic.bio/scientific-pre…

September is vascular disease awareness month. Peripheral artery disease (PAD) is a progressive condition that affects over 8 million Americans. Learn about the risk factors and prevention at vascularcures.org/peripheral-art…

PAD affects more than 10 million people in the U.S. It is more common in people who are 65 or older, but can occur at nearly any age. Get to know the symptoms of peripheral arterial disease during PAD Awareness Month: ow.ly/XpWy30lRhgB

Enjoyed presenting at #JLABS event in Beijing. Great to help build healthcare ecosystems all over the world! Thanks for the invite Sharon Chan Johnson & Johnson Innovation

Symic Bio selected The Best of the Liver Meeting at AASLD 2018 prnewswire.com/news-releases/…

Congrats to Symic CSO Glenn Prestwich on being elected as an AAAS Fellow! AAAS symic.bio/news/

#ICYMI: Consensus JLABS ‘Opportunities in China’ event: Although there are differences, there are still so many opportunities in China. All-star panel helped us finish #JPM19 strong! Thanks Symic Bio, Achelois Oncology, Qiming, LYFE Capital, Northern Light, & Sharon Chan #JLABS

Symic co-founder John Paderi participating in National Committee on US-China Relations' (ncuscr.org)Young Leaders Forum 2019. Local coverage here: sohu.com/a/305311032_71…

Listen to @CarolynBertozzi Stanford University on her career path in science, a few cool things in glycobiology, and Legos. The Long Run podcast. timmermanreport.com/2019/04/the-ro…

Dr. John Paderi speeaking about Symic Bio at UNC Pharmacy #PharmSci #CareerDevelopment

The last professional event of UNC-Chapel Hill AAPS for 2018-19 is now done & dusted. It was a fantastic year, and I am excited to be part of planning some great events. Today, we hosted Dr. John Paderi from Symic Bio, Inc at UNC Pharmacy with support from UNC TIBBS #PharmSci American Association of Pharmaceutical Scientists

Peripheral Arterial Disease (PAD) Therapeutics Market Status, Growth Analysis and Forecast 2018-2025 Get Full Information@ amecoresearch.com/market-report/… AstraZeneca Bayer | Pharmaceuticals Bristol-Myers Squibb Merck Sanofi Symic Bio Athersys Inc @miRagenRx ViroMed Co., LTD

Announcing close of $11M in new financing led by CIP Ventures prn.to/2W3Lk4I

Preclinical data presented at #CRT2018 support SB-030 mechanism of action, broad applicability and the promise of a matrix biology approach. Phase 2 clinical trial in vein graft failure expected to begin in 2H18: prnewswire.com/news-releases/…

Fantastic science &fun with #bme @UCDavisCoE grad students and Symic Bio colleagues at San Diego Glycobiology Symposium

At the BioCentury Future Leaders conference, CEO Ken Horne describes the broad capabilities of the Symic Bio platform and progress in the clinical development of matrix-targeting biotherapeutics

12-month results from SB-030 trial demonstrate improvement in efficacy outcome; trial in prevention of vein graft failure to begin second half of 2018: symic.bio/wp-content/upl…

Symic Bio co-founder and Senior Director of Translational Biology Kate Stuart presents preclinical results from liver fibrosis candidate with matrix-targeting mechanism of action at #ILC2018; clinical development planned for 2019: prnewswire.com/news-releases/…

President and Chief Business Officer Rinko Ghosh describes clinical and preclinical development programs at the ChinaBio® Group Partnering Forum: matrix-targeting therapeutics for peripheral vascular disease, osteoarthritis, liver fibrosis and oncology #ChinaPartnering

Symic Bio presentation at #ILC2018 receives "Best of ILC" recognition for preclinical liver fibrosis program: ilc-congress.eu/slide-decks/#b… (see General Hepatology summary slide presentation)